Anusha Nana

Dados Biográficos

ID9065803
NOMEAnusha Nana
PRENOMESAnusha
SOBRENOMENana
ASSINATURANANA A
AFILIAÇÕESUniversity of the Witwatersrand
ORCID0000-0003-0564-4043
VERIFICADOSim
TOTAL DE OBRAS3
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR3
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2021
ANO MAIS RECENTE DE PUBLICAÇÃO2024
ÍNDICE H0

  • Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants

    Open AccessCatherine Riou, Jinal N Bhiman et al.ARTICLEPLOS Global Public Health2024

    We report the safety and immunogenicity of fractional and full dose Ad26.COV2.S and BNT162b2 in an open label phase 2 trial of participants previously vaccinated with a single dose of Ad26.COV2.S, with 91.4% showing evidence of previous SARS-CoV-2 infection. A total of 286 adults (with or without HIV) were enrolled >4 months after an Ad26.COV2.S prime and randomized 1:1:1:1 to receive either a full or half-dose booster of Ad26.COV2.S or BNT162b2 …

  • Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa

    Open AccessNigel Garrett, Tarylee Reddy et al.ARTICLEPLOS Global Public Health2024

    Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare…

  • Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against Sars-CoV-2

    Open AccessMerryn Voysey, Sue Ann Costa Clemens et al.ARTICLEThe Lancet2021

    Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Afri…